Dr. Apar Kishor Ganti is an oncologist and internal medicine specialist at the University of Nebraska Medical Center. He is a physician scientist whose primary interests are lung cancer, malignant pleural mesothelioma, thymoma, head and neck cancers, and thyroid cancers.
Dr. Ganti is also an integral member of the Omaha VA Medical Center’s care team, where he cares for many veterans diagnosed with thoracic cancers. He has played a significant role in the implementation of the Lung Precision Oncology Program at that site, a program whose goal is to implement a multi-faceted and systematic program assessment with a targeted improvement plan to allow communication about lung cancer screening and clinical trials, thus increasing the number of patients screened for lung cancer and mesothelioma, facilitating access to clinical trials, and improving treatment and patient outcomes.
Education and Career
Dr. Ganti completed his medical training and residency at the B.J. Medical College in Pune, India. He completed an Internal Medicine Residency at the University of North Dakota and a Medical Oncology fellowship and Master’s Program in Clinical and Translational Research at the University of Nebraska Medical Center and College of Medicine.
In addition to his role as physician and researcher, Dr. Ganti is the Associate Director of Clinical Research at the UNMC Fred and Pamela Buffett Cancer Center, Chair of the Small Cell Lung Cancer Committee of the National Comprehensive Cancer Network, and Chair of the VA Clinical Science Research & Development Centralized Data Monitoring Committee. He is also a member of the Respiratory Committee of the Alliance for Clinical Trials in Oncology. He has served on the Board of Directors of the ACCRU (Academic & Community Cancer Research United) since 2013.
Dr. Ganti has also mentored medical students, residents, and fellows, as well as junior faculty engaged in research projects that have been presented at national or international meetings and/or published in peer-reviewed journals.
Dr. Ganti’s research is focused on the development of novel treatment approaches for patients who are not candidates for traditional therapies. His laboratory is focused on identifying novel prognostic and predictive biomarkers for these malignancies. In 2019, he was awarded The University of Nebraska Medical Center’s Distinguished Scientist Award, which recognizes researchers who have been among the most productive scientists at UNMC over the previous five years.